Arch, why don't you just re-register on RB as Arch ? We all know you as Arch anyway. I can't imagine why RB would remove you when there are so many bashers there that REALLY deserve removal.
What a rediculous move by RB ! Unbelievable !
I'd fight back.
Win.

Unbelievable ! Something BIG is coming, I think. Why else would we see so much GREEN and unbelievable volume ? I've waited a long time for the BIG one. Is this it ? We shall see....
Win.

Looking good today ! Moving up pre-open.
Win.

And, I might add....If we pass the .02 mark, we're going to .03 IMHO !
Won.

I'm not a technical whiz, but I think that .02 is the resistence point. We should be able to get there, once the dust settles in the next round. I'm just guessing, but it's looking good.
Win.

It's been a long time since we've seen a run like this. I sure wish I knew what's driving this baby today !
Win.

Dnaowner, I haven't a clue. All I know is that I've seen so many head-fakes that I'm gun shy about getting too optimistic. But, if we sustain today, we may be seeing a new trend. This is what I have been hoping for. I'm tired of seeing red when I know that DNAG is moving forward with ALL of their plans. At some point, the marketplace will know what a gem in the making DNAG is.
I'm hoping it's starting now.....
Win.

If we can sustain an upward movement today, then I would bet that something really nice is close to being announced. If not, then it's just another head-fake.
Fingers crossed.
Win

Thanks for the info, Frog. We are finally going to see our first monumental patent ! Excellent news. This will put us clearly in the lead. What sweet news today !
Win.

Now, we must wait for this patent to be granted. The fact that the 'allowance' has been granted still means we must wait for the actual 'granting approval', as I see it, but we have climbed the first hurdle. Isn't this correct ?
Win.

Ann, it sounds to me more like a family 'obligation' than anything else. George funded DNAP for quite a while. This just sounds like another venture of his. He's always into something from what I've seen.
Win.

Chris, yep, there are games being played- as always.
Geob, I doubt that the MM's are trying to hold us back for good reason. They're too busy trying to make money off of our sorry backs, lol. But hey, as Chris says...LOL.
Win.

Strange pattern today. Can't figure this out....
Win.

This sudden volume is very strange. Something must be up. We'll know very soon, I think.
Win

Fsail, I have heard of the DNAG (DNAP) Aol board from past references. Out of curiosity, what happened to that board ? It ended for what reason ? Thanks.
Win.

Ann, when I type DNAP it comes up as NASDAQ: DNAP !
I don't want to raise any false hopes, but hey, it looks nice anyway. I think it's just a temporary glitch.
Win.

I don't like this slide down. If there's news it HAS GOT TO BE BIG NEWS ! This is sickening.
Win.

OK, where's the meat ? Jeever, you can't hang your hat on this kind of stuff.
Win.

Stockboy, how do you know that there are no more deals in the works ? Believe me, there HAS to be a reason behind a move like this. We just don't have all the facts yet. I would calm down and wait to see what comes next. It may just be what we have all been waiting for + revenue. It is darkest before dawn.
Win.

Grati, I use Ameritrade. They had the new ticker and new share amount listed at the open the day of the split. They're tops in my book. I also love their free REAL TIME streamer. I can watch up to 20 stocks per page at once. Love that feature !
Win.

Interesting, Arch. I wonder what has caused the sudden increase in traffic at Ancestry by dna ? Could it just be the European market catching on ? There must have been some new marketing program going on there, or media attention, that's my guess.
You're a pretty good detective.
Win.

I'm anxiously awaiting tomorrow, the predicted event. We shall see....
Win.

Chris, can you pass that Novacaine around ? Ouch !
Win.

Wow ! here is the text:

Dear Shareholders,
You will probably note that we issued a news release and filed an 8k with the SEC stating that we have
entered into a stock purchase agreement to acquire an 18% interest in Biofrontera. This transaction
includes a possible ‘put’ purchase agreement with Heidelberg Innovations, a venture capital firm out of
Heidelberg, Germany. You may also recall that we had a previous arrangement with Biofrontera that
failed to materialize. However, since that time, conditions at Biofrontera have changed, and they are in
the midst of placing on the German Bond Market a high risk, convertible debenture instrument that would
require all the shareholders of Biofrontera to convert into a single class of common stock.
We were presented the opportunity to purchase a package, consisting of part debt and part equity, from a
German government agency known as tbg, which early on in the development of Biofrontera constructed
a complicated but beneficial financing package for Biofrontera’s start-up. We purchased that package for
1.5 million Euros with an additional package due later at 387K Euros. The instrument allowed us to
convert the debt portion of the package, cleaning up Biofrontera’s balance sheet and making a future bond
placement and hopefully a public offering possible. This effort by DNAPrint has removed substantial debt
from the Biofrontera balance sheet and has created a future equity value for us if the bond placement is
successful.
Why did we undertake this investment? First, we believe Biofrontera has a substantial potential market
valuation. We also believe, despite the earlier failure of the larger acquisition, that we should maintain a
relationship and pursue any and all opportunities to participate with Biofrontera and its shareholders in
the growth of that company. Second, we will continue to expand our relationship with Biofrontera
because they have two Phase 2 drugs that we can help develop, plus additional discovery compounds that
we might partner and/or license. Third, both Biofrontera and DNAPrint would like to have corresponding
facilities in each of their respective markets – DNAPrint would like to have a presence in Europe, and
Biofrontera would like to have a presence in the U.S. Finally, Biofrontera and DNAPrint believe that
their technologies are synergistic for the development of drugs for personalized medicine. Biofrontera has
the ability to isolate, identify and clone novel receptor pathways, and DNAPrint has the ability to identify
and isolate unique genetic markers expressed by individuals whereby these unique pathways may be
identified.
So over the coming months you may see additional investment in technologies between Biofrontera and
DNAPrint, some licensing, joint partnering as well as joint development and mutually beneficial
operations in each others’ home markets. We will also be sharing board members; currently Hector
Gomez, M.D., Ph.D., DNAPrint’s Chairman and Chief Medical Officer, and I are members of
Biofrontera’s supervisory board. The next objective for Biofrontera and the new supervisory board
members will be to assist Biofrontera in going public. If it can achieve that goal, you as DNAPrint
shareholders will be owners in Biofrontera through DNAPrint.
Richard Gabriel,
CEO and President
Company Contact:
Richard Gabriel
CEO and President
941 336-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

From the 8-k:

Anyone want to decifer this into simple language? I'm still sorting all this out:

"In addition, to induce the shareholders of Biofrontera to consent to the transaction, the Registrant entered into a put agreement with another Biofrontera shareholder, Heidelberg Innovation. Pursuant to this agreement, if by December 31, 2005 Biofrontera does not complete its current offering of debt securities for at least (euro)10 million, Heidelberg Innovation may require the Registrant to purchase Heidelberg Innovation's ownership interest in Biofrontera of approximately 49% for (euro)1.6 million (approximately $1.96 million).

Let's all give a cheer for Ann ! Thick or thin, she's busy reminding us all of what we have here. It's nice to see the bashers gone and the stock beginning a new chapter.
I'm in this until the end, as I always have been.
I seem to have this dream about DNAG that I can't put to rest. I still can't quite get used to calling this stock D-NAG, though.
There will come a day when it doesn't sound so strange.
Keep the faith all. I have remembered many of you from the beginning. Nice to see you're still here.
Win

Phil, it looks like all the longs who got nervous and sold before the R/S are slowly coming back in dribbles. Tis' good. Slow, but steady wins the race.
Take care,
Win

Raging Bull DNAP board disappears...I tried looking for a new DNAG board, but can't find one yet. If anyone finds the new board on R/B please post a link. Thanks.

Win

Press Release Source: DNAPrint genomics

DNAPrint genomics Upgrades Genotyping Platform
Tuesday July 12, 7:00 am ET

SARASOTA, Fla., July 12 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAG - News) today announced an upgrade in the throughput and cost efficiency of its automated Beckman Coulter GenomeLab SNPstream genotyping platform.

Beckman Coulter, which manufactures laboratory instrument systems for diagnostic tests and biological research, upgraded DNAPrint's SNPstream Ultra High Throughput (UHT) instrument from 12-plex to 48-plex capability, allowing for an approximate four-fold increase in throughput, or the rate at which it can read DNA sequences. The instrument reads DNA sequence from microarray slides (so-called DNA chips) containing about 18,000 nanospots. Since the upgrade in capability does not require commensurate increases in labor, the Company expects to enjoy a significant reduction in price per genotype. The upgrade was part of a planned expansion of DNAPrint's laboratory size, presence and capabilities as the Company grows to handle larger numbers of drug and diagnostics development projects.

"The upgrade will generate cost savings for the Company, a portion of which will be passed on to our clients," said Richard Gabriel, President and Chief Executive Officer of DNAPrint genomics. "We continue to improve our operations to meet the growing demand we are experiencing, not just in our internal research and development projects, but also in customer sales in Forensics, Ancestry and Genotyping services as well."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
CEO and President
941 336-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848


Source: DNAPrint genomics

Volume low. This could actually be good for DNAG. It seems that the R/S and new symbol have shaken out the traders and naked shorts. Let's see if it can last. One thing is for sure, I'm not used to seeing things so quiet, lol.
Win.

Volume 16,000 at 10:11. This feels weird to me. So quiet.
DNAG needs some caffeine. News, we need news.
Win

nuttin, I have never had ANY of my holdings do a reverse split. I have had many 'splits' and the symbol always remained the same. Where do you get your facts from ? Could you show us an example ?
Win.

Bag, Poor Melv must have found another 'mater' patch to rob. I miss chasing him away from my 'maters'. LOL.
Win

Bag, I'm not sure what the reason for the name change is, but one thing is for sure, there 'IS' a reason. I'm holding my breath for tomorrow and maybe the answer will come. Who knows.
Take care,
Win

I also meant to add to my previous post that:
Buying a small drug company which is already listed on the regular stock exchange, which also has some PROFITS would be a he$# of a good way to get out of a financial debacle and get listed on the regular stock exchange without any the hassle.
Remeber, DNAP began and was listed on the Pink sheets a few years ago by purchasing a small Utah company listed on the Pink Sheets. Why wouldn't they want to take the easiest route again by buying another company which is already listed on the regular exchange ?
I remember when Dr. Frudakis talked about his goals and one of those goals was to get OFF the OTC !
Just trying to reason this out. It's a pipe-dream, perhaps.
Win.

What if DNAP decides to look for and buy a small drug company which is already listed on the regular stock exchange and isn't a penny stock ? What would that make DNAP ? Think about it.
Just speculating on ideas.
Win.

Jeeve, you have IHUB mail.
Win.

jeever, it would benefit DNAP to come out with the 'big' news very quickly. Let's hope that this is their 'plan' !!
Win.

DNAPrint genomics to Effect 1-for-20 Stock Consolidation on Tuesday, July 12
Wednesday July 6, 7:00 am ET

SARASOTA, Fla., July 6 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP - News) today announced that its Board of Directors has authorized a 1-for-20 consolidation of the Company's stock, effective at 12:01 a.m. Eastern time on Tuesday, July 12, 2005.

Shareholders at the Company's annual meeting on June 23 approved an amendment to the Company's Articles of Incorporation authorizing a stock combination of at least 1-for-10 but no more than 1-for-20 with the exact ratio established by the Board of Directors.

Following the stock consolidation, DNAPrint genomics will have approximately 62,000,000 shares outstanding.

"The stock consolidation will enable DNAPrint genomics to access up to $40 million in capital from equity line draws for future growth and potential acquisitions," stated President and Chief Executive Officer Richard Gabriel. "The central focus of our strategic plan is to build up our pharmaceutical division by placing new drugs into the pipeline. At the same time, we plan to expand our forensics division based on the growing success of our product line for law enforcement."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
President and CEO
941-366-3400

-or-

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848


Source: DNAPrint genomics


Mail to Friend Email Story

Alerts Set News Alert

Printer Version Print Story


Related Quote
chart
DNAP.OB 0.01 0.00 News
View Detailed Quote
Delayed 20 mins
Providers - Disclaimer
Related News Stories
· DNAPRINT GENOMICS INC Files SEC form 8-K, Material Modifications, Financial Statements and Exhibits - EDGAR Online (Tue Jul 5)
· DNAPrint genomics Plays Key Role in Investigation of 11-Year-Old Florida Murder Case - PR Newswire (Thu Jun 30)
· DNAPrint genomics Chairman Hector Gomez Tells Annual Meeting That Company Broadens Its Activities - PR Newswire (Fri Jun 24)
· DNAPrint CEO Richard Gabriel's Interview With Wall Street Reporter Magazine Available Via Web Cast - PR Newswire (Wed Jun 22)
More...
· By industry: Medical/pharmaceutical
Top Stories
· Zions Bancorp to Buy Amegy in $1.7B Deal - AP (7:47 am)
· Oil Prices Top $60 a Barrel on Supply Fears - AP (8:33 am)
· Stocks Set to Open Lower on Oil Prices - AP (8:53 am)
· GE Unit to Acquire CIT Aircraft Assets - AP (8:38 am)
More...
· Most-emailed articles
· Most-viewed articles

Copyright © 2005 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Ad Feedback
Copyright © 2005 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the co

Ann, that patent was filed when Tony was with Corixa. They own the patent rights, not Tony. It's easy to see why he left Corixa and started his own company.
Win.